Abstract Library

#4045 Radio-guided surgery with a new generation β-probe for radiolabelled somatostatin analogue, in patients with small intestinal neuroendocrine tumors – A Phase II surgical trial

Introduction: Radio-guided surgery (RGS) proved to be promising in neuroendocrine tumors (NETs). Previous studies showed high sensitivity but low specificity using gamma probes to detect radiation emitted by radio-labelled somatostatin analogues.

Conference:

Presenting Author: Danieli M

Authors: Bertani E, Fumagalli Romario U, Collamati F, Mattana F, Fazio N,

Keywords: Radio-guided surgery, small-intestinal neuroendocrine tumor, small-intestinal resection, beta-probe, radiolabelled somatostatine analogues, surgery, lymphadenectomy,

#3724 Tackling drug activity and resistance mechanisms in neuroendocrine tumors treated with cabozantinib

Introduction: Neuroendocrine tumors (NETs) are highly vascularized malignancies and angiogenesis plays a relevant role in cell proliferation and survival. Nowadays, innovative therapies have amplified the paradigm treatment of NETs. Among the compounds with anti-vascular properties, cabozantinib (CAB) appeared promising.

Conference:

Presenting Author: Cella C

Authors: Cella C, Cazzoli R, Fazio N, de Petro G, Gaudenzi G,

Keywords: Neuroendocrine tumor, angiogenesis, zebrafish model, mouse model.,

#3674 COVID-19 in patients with neuroendocrine neoplasms – Two-year results of a worldwide survey (The INTENSIVE study)

Introduction: Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021.

Conference:

Presenting Author: Gervaso L

Authors: Fazio N, Gervaso L, Halfdanarson T, Sonbol M, Pusceddu S,

Keywords: neuroendocrine, NEN, COVID-19, SARS-CoV-2,

#3541 Surgical treatment of type 1 gastric neuroendocrine tumors: A 20-years single center experience

Introduction: Gastric neuroendocrine tumors (g-NETs) are rare, differentiated and usually indolent lesions; they include 3 types based on their pathogenesis. Type 1 are usually treated endoscopically according to their size, depth of invasion and presence of lymph-node (LN) metastases, types 3 are generally treated surgically. There is no clear evidence of the most accurate staging strategy for regional LN metastases.

Conference:

Presenting Author: Bertani E

Authors: Colombo S, Fumagalli Romario U, Pisa E, Spada F, Fazio N,

Keywords: Pet, gastric neuroendocrine tumor, surgery,

#3533 Identification of proangiogenic plasmatic biomarkers in patients with advanced grade 1/2 pancreatic (pan) and gastrointestinal (gi) neuroendocrine tumors (NETs) treated with Lenvatinib: A subanalysis from the TALENT phase II clinical trial

Introduction: TALENT phase II trial provided evidence of the efficacy of Lenvatinib in patients with panNETs and giNETs. However, no predictive biomarker has been associated to antiangiogenic treatment benefit to date.

Conference:

Presenting Author: Garcia-Alvarez A

Authors: Garcia Alvarez A, Hernando J, Jimenez-Valero G, Martinez A, Fazio N,

Keywords: Lenvatinib, Angiogenesis, Ang2, VEGFR2,